Program Announcement

Department of Defense Congressionally Directed Medical Research Programs

Prostate Cancer Research Program

Clinical Trial Award

Funding Opportunity Number:  W81XWH-11-PCRP-CTA
Catalog of Federal Domestic Assistance Number:  12.420

SUBMISSION AND REVIEW DATES AND TIMES

- Pre-application Submission Deadline:  5:00 p.m. Eastern time (ET), June 10, 2011
- Invitation to Submit an Application:  July 13, 2011
- Application Submission Deadline:  11:59 p.m. ET, September 1, 2011
- Scientific Peer Review:  October 2011
- Programmatic Review:  December 2011

New for fiscal year 2011 (FY11): The formal protocol for the proposed clinical trial should not be submitted as the Clinical Trial Award application. A formal protocol will be requested if the application is recommended for funding.

New for FY11: The Grants.gov Research & Related Budget form is a mandatory component of all Grants.gov application packages.
TABLE OF CONTENTS

I. Funding Opportunity Description .......................................................................................3
   A. Program Description ........................................................................................................3
   B. Award Information...........................................................................................................4
   C. Eligibility Information .....................................................................................................6
   D. Funding ............................................................................................................................6

II. Submission Information .......................................................................................................7
   A. Where to Obtain Application Package .............................................................................7
   B. Pre-Application Submission Content and Form ..............................................................7
   C. Application Submission Content and Form ...................................................................10
   D. Submission Dates and Times .........................................................................................18
   E. Other Submission Requirements ....................................................................................19

III. Application Review Information .......................................................................................19
   A. Application Review and Selection Process ...................................................................19
   B. Application Review Criteria ..........................................................................................19
   C. Recipient Qualification ..................................................................................................22
   D. Application Review Dates .............................................................................................23
   E. Notification of Application Review Results .................................................................23

IV. Administrative Actions .......................................................................................................23
   A. Rejection ........................................................................................................................23
   B. Modification ..................................................................................................................23
   C. Withdrawal ....................................................................................................................24
   D. Withhold ........................................................................................................................24

V. Award Administration Information ..................................................................................24
   A. Award Notice ................................................................................................................24
   B. Administrative and National Policy Requirements .......................................................24
   C. Reporting .......................................................................................................................25
   D. Award Transfers ............................................................................................................25
   E. Pre-Award Meeting ........................................................................................................25

VI. Agency Contacts ..............................................................................................................25
   A. CDMRP Help Desk .......................................................................................................25
   B. Grants.gov Contact Center ............................................................................................25

VII. Application Submission Checklist .....................................................................................26
I. FUNDING OPPORTUNITY DESCRIPTION

A. Program Description

The Prostate Cancer Research Program (PCRP) was established in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY10 totaled $1.05 billion. The FY11 appropriation is $80 million (M).

The overall goal of the FY11 PCRP is to find and fund innovative, high-impact research that will eliminate death and suffering from prostate cancer. Specifically, the PCRP seeks to support innovative, high-risk, high-gain research with potential near-term impact; sponsor multidisciplinary synergistic research; fund translational studies to promote the fluid transfer of knowledge between bedside and bench; invest in research on patient survivorship (quality of life); foster the next generation of prostate cancer investigators through mentored research; and promote research into prostate cancer health disparities.

PCRP Overarching Challenges

Consistent with the program’s overall goal, each PCRP funding opportunity either requires or encourages (see Award Information below) applications to address one of the following PCRP overarching challenges:

- Develop effective treatments for advanced prostate cancer (i.e., disease relapse with no available curative therapy)
- Distinguish aggressive from indolent disease

PCRP Focus Areas (revised for FY11)

All applications for FY11 PCRP funding opportunities should also address at least one of the following PCRP focus areas:

Biomarkers: Discovery and validation of biomarkers for the detection, prediction of response to therapy, prognosis, and progression of prostate cancer.

Genetics: Understanding the genetics and epigenetics responsible for susceptibility, disease progression, and treatment outcomes for clinically significant prostate cancer.

Imaging: Development of new anatomic and molecular imaging technology for the detection and management of prostate cancer.

Survivorship: Studies on the impact of treatment, nutrition, metabolism, and exercise on the well-being of prostate cancer patients and their families.

Therapy: Identification of new targets, pathways, and therapeutic modalities, including immunotherapy and mechanisms of resistance.

Tumor Biology and Immunology: Understanding prognosis and progression of prostate cancer.
B. Award Information

The PCRP Clinical Trial Award mechanism was first offered in FY01. Since then, 97 Clinical Trial Award applications have been received, and 18 have been recommended for funding.

The PCRP Clinical Trial Award supports rapid execution of clinical trials (Phase 0/I, Phase I, Phase I/II, or Phase II for drugs, Class II or III for devices) to test novel approaches with the potential to have a major impact on the treatment or management of prostate cancer. **Funding from this award mechanism must support a clinical trial and cannot be used for preclinical research studies.** A clinical trial is defined as a prospective accrual of patients where an intervention (i.e., drug, device, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction. Exploratory clinical trials (Phase 0) may be submitted for the PCRP Clinical Trial Award, but they must be accompanied by a Phase I clinical trial (Phase 0/I). Principal Investigators (PIs) must clearly specify in their applications which type of clinical trial, including phase or class designation (if applicable), is being proposed. PIs are encouraged to accompany their trials with correlative studies that address one or more of the PCRP focus areas (see Program Description above). PIs conducting correlative studies must describe in detail the study aims, procedures or methods, and plans for data management and analysis, including an appropriately powered statistical plan. For more information on clinical trials and phase/class of study, a Human Subject Resource Document is provided at [https://cdmrp.org/Program_Announcements_and_Forms/](https://cdmrp.org/Program_Announcements_and_Forms/).

Studies in a broad range of areas related to prostate cancer clinical management and care will be accepted under this PCRP Clinical Trial Award, including but not limited to:

- Evaluations of novel drugs, biologics, or devices
- Survivorship
- Diet
- Quality of life
- Psychosocial interventions
- Behavioral studies

**All applications for the Clinical Trial Award are highly recommended to address one of the FY11 PCRP overarching challenges.** The PCRP seeks to fund projects from the wide spectrum of basic to clinical research; however, if the proposed project does not address one of the overarching challenges, the application should provide a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care.
The following are important aspects of submission for the PCRP Clinical Trial Award:

- The application should include a thorough discussion of the potential for the proposed intervention and study results to lead to a major impact on the treatment or management of prostate cancer.

- **New for FY11:** The application must include documentation of an existing Investigational New Drug (IND) or Investigational Device Exemption (IDE), if applicable.

- The intervention to be tested should be based on sound scientific rationale that is established through logical reasoning, critical review, and analysis of the literature.

- The inclusion of preliminary data that are relevant to the proposed research is required; any unpublished preliminary data should originate from the laboratory of the PI or collaborators named on this application.

- The application should demonstrate availability of and access to a suitable human subject population that will support a meaningful outcome for the study. The PI should discuss how accrual goals will be achieved, and how standards of care may impact the study population.

- The application should demonstrate documented availability of and access to the drug/compound, device, and/or materials needed.

- The proposed clinical trial should include clearly defined and appropriate endpoints.

- The application should include a detailed statistical analysis plan, including a power analysis reflecting sample size projections that will clearly answer the objectives of the study.

- The proposed clinical trial is expected to begin no later than 12 months after the award date.

- **New for FY11:** PIs must discuss how the clinical trial will be funded to its planned completion with either: support with funds from the PCRP, support from the applicant institution, and/or support from another agency or entity. Documentation of necessary funding from other sources, if applicable, is required, and will be requested at a later date for Clinical Trial Award applications recommended for funding.

- **New for FY11:** The application should include a Transition Plan that describes a clear path to further develop the intervention after the end of the award period of performance.

**Use of Human Subjects and Human Anatomical Substances:** All Department of Defense (DOD)-funded research involving new and ongoing research with human subjects and human anatomical substances must be reviewed by the local Institutional Review Board (IRB) of record. **However, IRB approval at the time of submission is NOT required.** In addition, these studies must also be reviewed and approved by the US Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP), Human Research Protection Office (HRPO). The HRPO is mandated to comply with specific laws and directives governing all research involving human subjects that is supported by the DOD. These laws and directives are
rigorous and detailed, and will require information in addition to that supplied to the IRB of record. Allow a minimum of 4 months for regulatory review and approval processes. Refer to the General Application Instructions, Appendix 5, for more information.

C. Eligibility Information

- PIs must be independent investigators at or above the level of Assistant Professor (or equivalent).
- Cost sharing/matching is not an eligibility requirement.
- Refer to the General Application Instructions, Appendix 1, for general eligibility information.

D. Funding

- The maximum period of performance is 3 years.
- The maximum allowable direct costs amount for the entire period of performance is $375,000 plus indirect costs.
- All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.
- The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.
- Regardless of the period of performance proposed, the applicant may not exceed the maximum allowable direct costs. Indirect costs shall be proposed in accordance with the organization’s negotiated rate agreement.

Refer to the General Application Instructions, Section II.C., for budget regulations and instructions for the Research & Related Budget form. In addition, for this award mechanism, direct costs:

Must be requested for:

- Salary for a Study Coordinator(s) who will guide the clinical protocol through IRB of record review and other regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate human subject accrual.
- Travel to a pre-award meeting at Fort Detrick, Maryland. At a minimum, the PI and Clinical Research Coordinator are expected to attend the pre-award meeting, although up to three individuals may attend.
- The PI to travel to one 3½-day PCRP IMPaCT (Innovative Minds in Prostate Cancer Today) Meeting, which is held to disseminate the results of PCRP-sponsored research.

May be requested for (not all-inclusive):

- Other salary
- Research-related human subject costs
- Clinical research costs
The Office of the Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately $1.8M of the $80M FY11 PCRP appropriation to fund approximately 3 Clinical Trial Award applications, depending on the quality and number of applications received. Funding of applications received in response to this Program Announcement/Funding Opportunity is contingent upon the availability of Federal funds for this program.

II. SUBMISSION INFORMATION

Submission is a multi-step process requiring both (1) pre-application submission through the CDMRP eReceipt System (https://cdmrp.org/) and (2) application submission through Grants.gov (http://www.grants.gov/).

Submission of the same research project to different funding opportunities within the same program and fiscal year is discouraged. The Government reserves the right to reject duplicative applications.

A. Where to Obtain the Application Package

To obtain the complete application package, including all required forms, perform a Grants.gov (http://www.grants.gov/) basic search using the Funding Opportunity Number: W81XWH-11-PCR-PCTA.

B. Pre-Application Submission Content and Form

All pre-application components must be submitted by the PI through the CDMRP eReceipt System (https://cdmrp.org/). Because the invitation to submit an application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

PIs and organizations identified in the application should be the same as those identified in the pre-application. No change in PI will be allowed after the pre-application deadline. If a change in organization is necessary after submission of the pre-application, the PI must contact the CDMRP Help Desk at help@cdmrp.org or 301-682-5507. A change in organization after submission of the pre-application will be allowed only at the discretion of the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer.

The pre-application consists of the following components, which are organized in the CDMRP eReceipt System by separate tabs (refer to the General Application Instructions, Section II.B., for additional information on pre-application submission):
• Application Information – Tab 1
• Application Contacts – Tab 2
• Collaborators and Conflicts of Interest (COI) – Tab 3
• Required Files – Tab 4

Preproposal Narrative (three-page limit): The Preproposal Narrative page limit applies to text and any figures, tables, graphs, photographs, diagrams, chemical structures, pictures, pictorials, and cartoons.

The Preproposal Narrative should include the following:

○ **Background/Rationale:** Concisely describe the ideas and reasoning behind the proposed research, including literature citations as needed and brief discussion of preliminary studies and/or preclinical data that led to the development of the proposed clinical trial. Unpublished data should originate from the laboratory of the PI or collaborators named on this application. Clearly describe the intervention and, if applicable, its target and mechanism of action in prostate cancer.

○ **Objectives/Specific Aims/Hypotheses:** Briefly describe the purpose and objectives of the study, including specific aims and/or study questions/hypotheses.

○ **Study Design:** State the type of study to be performed (e.g., prospective, randomized, controlled, etc.) and briefly outline the proposed methodology.
  - Define the study variables and describe how they will be measured.
  - Describe the methods that will be used to obtain an appropriately powered sample of human subjects from the accessible population.
  - Concisely describe the research team’s expertise in conducting clinical trials, including discussion of key coordinating activities (e.g., recruit and consent of patients, maintain records, administer drug, etc.).
  - Briefly discuss the feasibility of initiating the clinical trial within 12 months of the award date, including anticipated milestones such as:
    - Applicable regulatory approvals (documentation of an existing IND/IDE for the intervention, if applicable, must be included with the full application, if invited, to the PCRP Clinical Trial Award)
    - Intellectual and material property permissions
    - Other milestones
Clinical Impact:  Describe how the proposed study, if successful, will have a major impact towards improving prostate cancer treatment and/or management and ultimately contribute to eliminating death and suffering from prostate cancer.

Overarching Challenges and Focus Areas:  Describe how the proposed study is responsive to one of the PCRP overarching challenges.  If the proposed project does not address one of the overarching challenges, provide a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care.  In addition, if correlative studies are proposed in addition to the clinical trial, state at least one of the PCRP focus areas to which the proposed studies are responsive.

Pre-Application Supporting Documentation:  The items to be included as supporting documentation for the pre-application are limited to:

- References Cited (one-page limit):  List relevant references using a standard reference format that includes the full citation (i.e., author(s), year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).  The inclusion of Internet URLs to references is encouraged.

- List of Abbreviations, Acronyms, and Symbols:  Provide a list of abbreviations, acronyms, and symbols.

- Key Personnel Biographical Sketches (four-page limit per individual)

- Submit Pre-application – Tab 5

- Other Documents Tab

No additional documents are required.

Pre-Application Screening

- Pre-Application Screening Criteria

To determine the technical merits of the pre-application and the relevance to the mission of the DOD and CDMRP, pre-applications will be screened by the PCRP Integration Panel (IP) based on the following criteria:

- Clinical Impact:  To what degree the proposed intervention and study could have a major impact on prostate cancer by addressing one of the PCRP overarching challenges or another critical issue in disease treatment or management.

- Research Strategy:  How well the rationale and specific aims support the trial’s objective(s), and to what degree the project is likely to initiate within 12 months of award date.
 ○ **Personnel:** How the personnel’s background and expertise are appropriate to accomplish the proposed research (e.g., statistical expertise, expertise in prostate cancer and clinical studies).

- **Notification of Pre-Application Screening Results**

  Following the pre-application screening, PIs will be notified of whether or not they are invited to submit an application; however, they will not receive feedback (e.g., a critique of strengths and weaknesses) on their pre-application. Pre-application notification dates are indicated on the title page of this Program Announcement/Funding Opportunity.

**C. Application Submission Content and Form**

*Applications will not be accepted unless the PI has received a letter of invitation.*

Each application submission must include the completed application package of forms and attachments provided in Grants.gov for this Program Announcement/Funding Opportunity. The application package is submitted by the Authorized Organizational Representative (AOR) through the Grants.gov portal (http://www.grants.gov/).

**Grants.gov application package components:** For the PCRP Clinical Trial Award, the Grants.gov application package includes the following components (refer to the General Application Instructions, Section II.C., for additional information on application submission):

1. **SF 424 (R&R) Application for Federal Assistance Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

2. **Attachments Form**

   New for FY11: *The Project Narrative is NOT the formal clinical trial protocol (as in previous years). Instead, all essential elements of the proposed clinical trial necessary for scientific review must be included as directed in Attachment 1 (the Project Narrative) and Attachments 6-8 described below. Failure to submit these attachments as part of the application package will result in rejection of the entire application.*

   - **Attachment 1: Project Narrative (20-page limit):** Upload as “ProjectNarrative.pdf.”

     Describe the proposed project in detail using the outline below.

     a. **Background:** Describe in detail the rationale for the study and include a literature review, preliminary studies, and/or preclinical data that led to the development of the proposed clinical trial; unpublished preliminary data should originate from the laboratory of the PI or collaborators named on this application. The background section should clearly support the choice of study variables and should explain the basis for the study questions and/or study hypotheses. This section should establish the relevance of the study and explain the applicability of the proposed findings.
If the proposed clinical trial was initiated using other funding prior to this application, explain the history and background of the clinical trial and declare the source of prior funding. Specifically identify the portions of the study that will be supported with funds from this award. If any portion of the study will be supported by funds other than those previously obtained to initiate the study or other than those from this award, discuss all sources of funding required to fully support the study to its planned completion. Documentation of all sources of necessary funding will be required if the application is recommended for funding. The Government reserves the right to administratively withdraw applications unable to demonstrate full support for the proposed study.

b. Objectives/Specific Aims/Hypotheses: Provide a description of the purpose and objectives of the study with detailed specific aims and/or study questions/hypotheses.

c. Study Design: Describe the type of study to be performed (e.g., prospective, randomized, controlled, etc.) and outline the proposed methodology in sufficient detail to show a clear course of action.
  o Identify the intervention to be tested and describe the projected outcomes.
  o Define the study variables and describe how they will be measured. Include a description of appropriate controls and the endpoints to be tested.
  o Describe the methods that will be used to recruit a sample of human subjects from the accessible population (i.e., convenience, simple random, stratified random).
  o Describe the human subject-to-group assignment process (e.g., randomization, block randomization, stratified randomization, age-matched controls, alternating group, or other procedures), if applicable. Explain the specific actions to accomplish the group assignment (e.g., computer assignment, use of table of random numbers).
  o Describe the reliability and validity of psychometric measures, if applicable.

d. Statistical Plan and Data Analysis: Include a complete power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. Specify the approximate number of human subjects that will be enrolled. If multiple study sites are involved, state the approximate number to be enrolled at each site. Describe the data analysis plan in a manner that is consistent with the study objectives.

- Attachment 2: Supporting Documentation. Start each document on a new page. Combine and upload as a single file named “Support.pdf.” If documents are scanned to pdf, the lowest resolution (100 to 150 dpi) should be used. Each component has no page limit unless otherwise noted.
  o References Cited: List the references cited (including URLs if available) in the project narrative using a standard reference format that includes the full citation.
(i.e., author[s], year published, title of reference, source of reference, volume, chapter, page numbers, and publisher, as appropriate).

- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.

- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project, and any additional facilities or equipment proposed for acquisition at no cost to the USAMRMC. Indicate if Government-owned facilities or equipment are proposed for use.

- **Publications and/or Patent Abstracts (five-document limit):** Include relevant publication URLs and/or patent abstracts. If publications are not publicly available, then they must be included. Extra items will not be reviewed.

- **Letters of Organizational Support:** Provide a letter (or letters, if applicable), signed by the Department Chair or appropriate organization official, reflecting the laboratory space, equipment, and other resources available for the project.

- **Letters of Collaboration (if applicable):** Provide a signed letter from each collaborating individual or organization that will demonstrate that the PI has the support or resources necessary for the proposed work.

- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations. Disclose any patents, issued or pending, and/or licenses, granted and/or pending, with respect to the intervention. Discuss and document availability of and access to the intervention. Provide documentation of access to and permission to use all intellectual and material property, as applicable.

- **Data and Research Resources Sharing Plan:** Describe how data and resources generated during the performance of the project will be shared with the research community. Refer to the General Application Instructions, Appendix 4, for more information about the CDMRP expectations for making data and research resources publically available.

- **Attachment 3: Technical Abstract (one-page limit):** Upload as “TechAbs.pdf.”

  - Describe the proposed research project, including the following elements: Background, Objective/Hypothesis, Study Design and Specific Aims, and Clinical Impact. The technical abstract is used by all reviewers; however, programmatic reviewers do not have access to the full application and rely on the technical abstract for appropriate description of the project’s key aspects.

- **Attachment 4: Public Abstract (one-page limit):** Upload as “PublicAbs.pdf.”

  Public abstracts should be written using the outline below. Do not duplicate the technical abstract. The public abstract is used by consumer peer reviewers along with other components of the application package.
○ Describe the scientific objective and rationale for the proposed project in a manner that will be readily understood by readers without a background in science or medicine.

○ Describe the ultimate applicability of the research.
  − What types of patients will it help, and how will it help them?
  − What are the potential clinical applications, benefits, and risks?

- Attachment 5: Statement of Work (SOW) (three-page limit): Upload as “SOW.pdf.” Refer to the General Application Instructions, Section II.C., for detailed information.


  a. Study Population: Describe the target population (to whom the study findings will be generalized) and the nature, approximate number and pertinent demographic characteristics of the accessible population at the study site (population from which the sample will be recruited/drawn). Demonstrate that the research team has access to the proposed study population. Furthermore, discuss past efforts in recruiting human subjects from the target population for previous clinical trials (if applicable), any potential barriers to accrual and plans for addressing unanticipated delays. Include justification of any age, race, or ethnicity limitations provided.

  b. Inclusion/Exclusion Criteria: List the inclusion and exclusion criteria for the proposed clinical trial. Inclusion/exclusion criteria should take into consideration the specific risk profile of the studies to be conducted and the standard of care for that patient population. Provide detailed justification for exclusions.

   Inclusion of Minorities in Study. Consistent with the Belmont Report and congressional legislation, special attention is given to inclusion of minorities in studies funded or supported by the USAMRMC. This policy is intended to promote equity both in assuming the burdens and in receiving the benefits of human subjects research. Include an appropriate justification if minorities will be excluded from the clinical trial.

  c. Description of the Recruitment Process: Explain methods for identification of potential human subjects (e.g., medical record review, obtaining sampling lists, healthcare provider identification).

    ○ Describe the recruitment process in detail. Address how potential human subjects will be identified, who will recruit them, and what methods will be used to recruit them.

    ○ Include a detailed description of and justification for the compensation plan if the human subjects will be compensated for participation in the study.

    ○ Describe the recruitment and advertisement materials.
d. **Description of the Informed Consent Process**: Specifically describe the plan for obtaining informed consent from human subjects.

- Identify who is responsible for explaining the study, answering questions, and obtaining informed consent.
- Include information regarding the timing and location of the consent process.
- Address issues relevant to the mental capacity of the potential human subject (e.g., altered capacity due to administration of any mind-altering substances such as tranquilizers, conscious sedation or anesthesia, brain injury, stress/life situations, or human subject age), if applicable.
- Address how privacy and time for decision making will be provided, and whether or not the potential human subject will be allowed to discuss the study with anyone before making a decision.
- Consider the need for obtaining ongoing consent or for re-assessing capacity over the course of a long-term study, and describe any relevant procedures to assure continued consent.
- If human subjects who cannot give their own consent to participate will be included in the study, describe the plan for the consent of the individual’s Legally Authorized Representative (LAR) to be obtained prior to the human subject’s participation in the study. State law defines who may act as the LAR. The IRB of record should be consulted for guidance regarding who can serve as LAR for research at the study site. Note: The PI must describe a clear intent to benefit for human subjects who cannot give their own consent to participate in the proposed clinical trial to be in compliance with Title 10 United States Code Section 980 (10 USC 980) ([http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=browse_usc&docid=Cite:+10USC980](http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=browse_usc&docid=Cite:+10USC980)). Refer to the General Application Instructions, Appendix 5, for more information.
- Provide a draft in English of the proposed Informed Consent Form. A plan for ensuring that human subjects’ questions will be addressed during the consent process and throughout the trial should be included.

**Assent.** If minors or other populations that cannot provide informed consent are included in the proposed clinical trial, a plan to obtain assent (agreement) from those with capacity to provide it, or a justification for a waiver of assent should be provided. PIs should consult with their IRB of record to identify the conditions necessary for obtaining assent.

e. **Screening Procedures**: List and describe any evaluations (e.g., laboratory procedures, history, or physical examination) that are required to determine eligibility/suitability for study participation and the diagnostic criteria for entry. As some screening procedures may require a separate consent or a two-stage consent process, informed consent must be obtained prior to initiation of any procedures for the purpose of determining eligibility.
f. **Risks/Benefits Assessment:**

**Foreseeable risks:** Clearly identify all study risks. Study risks include any risks that the human subject is subjected to as a result of participation in the clinical trial. Consider psychological, legal, social, and economic risks as well as physical risks. If the risks are unknown, this should be stated. Identify any potential risk to the study personnel (if applicable).

**Risk management and emergency response:**

- Describe all safety measures to minimize and/or eliminate risks to human subjects and study personnel, or to manage unpreventable risks. Include safeguards and planned responses such as dose reduction or stopping criteria based on toxicity grading scales or other predetermined alert values.
- Discuss the overall plan for provision of emergency care or treatment for an adverse event for study-related injuries, to include who will be responsible for the cost of such care.
- Address any special precautions to be taken by the human subjects before, during, and after the study (e.g., medication washout periods, dietary restrictions, hydration, fasting, etc.).
- Describe any special care (e.g., wound dressing assistance, transportation due to side effects of study intervention impairing ability to drive) or equipment (e.g., thermometers, telemedicine equipment) needed for human subjects enrolled in the study.

**Potential benefits:** Describe real and potential benefits of the study to the human subject, a specific community, or society.

- **Attachment 7: Intervention (no page limit):** Upload as “Intervention.pdf.” The Intervention attachment should include the components listed below.
  
  a. **Description of the Intervention:** As applicable, the description of the intervention should include the following components: source, dose, schedule, administration route, washout period, duration of the intervention, and concomitant medications allowed. Description of devices should include detailed operational instructions, and any potential risks to users, and intended benefits. Other types of interventions should be fully described.

  b. **Study Procedures:** Describe the expected experience that the human subject will have with the intervention. Provide sufficient detail in chronological order for a person uninvolved in the study to understand what the human subject will experience. Provide a schedule (e.g., flowchart or diagram) of study evaluations and follow-up procedures.

- **Attachment 8: Data Management (no page limit):** Upload as “Data_Manage.pdf.” The Data Management attachment should include the components listed below.
  
  a. **Data Management:** Describe all methods used for data collection to include the following:
**Identifiers:** Describe the unique identifiers or specific code system to be used to identify human subjects (if applicable).

**Confidentiality:**

- Explain measures taken to protect the privacy of study human subjects and maintain confidentiality of study data. Strategies to protect the privacy and confidentiality of study records, particularly those containing identifying information, should be addressed.
- Address who will have access to study records, data, and specimens, including an acknowledgment that representatives of USAMRMC are eligible to review study records.
- Address requirements for reporting sensitive information to state or local authorities.

**Disposition of data:** Describe where data (both electronic and hard copy) will be stored, who will keep the data, how the data will be stored, and the length of time data will be stored.

**Sharing study results:** In cases where the human subject could possibly benefit medically or otherwise from the information, explain whether or not the results of screening and/or study participation will be shared with human subjects or their primary care provider, to include results from any screening or diagnostic tests performed as part of the study.

**b. Laboratory Evaluations:**

**Specimens to be collected, schedule, and amount.** All specimens that will be collected for study purposes must be clearly stated. The collection schedule and amount of material collected must also be clearly described.

**Evaluations.** Describe all evaluations that will be made for study purposes. Explain how the results of laboratory evaluations will be used to meet the objectives of the study (or to monitor safety of human subjects).

**Storage.** Describe specimen storage, to include where, how long, any special conditions required, labeling, and disposition. Outline the plan to store specimens for future use to include considerations for informed consent and providing human subjects with an opportunity to decline participation in the study.

**Laboratories performing evaluations and special precautions.** Identify the laboratory performing each evaluation, as well as any special precautions that should be taken in handling the samples. Special precautions that should be taken by the human subject before, during, or after the laboratory procedure should be clearly defined. If transport of samples is required, describe provisions for ensuring proper storage during transport.

- **Attachment 9: Study Personnel and Organization (no page limit):** Upload as “Personnel.pdf.” The Study Personnel and Organization attachment should include the components listed below.
a. **Principal Investigator/Study Staff:** Provide an organizational chart identifying key members of the study team including institution/center/department. Briefly describe their roles on the project. A medical monitor (external to the study and not reimbursed by the study) and study coordinator(s) should be included.

b. **Study Management Plan:** Provide a plan for ensuring the standardization of procedures among staff and across sites (if applicable). If the proposed clinical trial is multi-institutional, plans for communication and data transfer between the collaborating institutions, as well as how data, specimens, and/or imaging products obtained during the study will be handled, should be included. Provide a plan for real-time communication among collaborating institutions (if applicable).

- **Attachment 10: Surveys, Questionnaires, and Other Data Collection Instruments, if applicable (no page limit):** Upload as “Surveys.pdf.” The Surveys, Questionnaires, and Other Data Collection Instruments attachment should include a copy of the most recent version of surveys, questionnaires, data collection forms, rating scales, interview guides, or other instruments. For each instrument, describe how the information collected is related to the objectives of the study.

- **Attachment 11: Impact Statement (one-page limit).** Upload as “Impact.pdf.” Explain in detail why the proposed research project is important to the overall goal of eliminating death and suffering from prostate cancer. Include the components listed below.
  - Identify the human subject population(s) that will participate in the proposed intervention, and describe the potential impact of the proposed clinical trial on the outcomes of individuals within the targeted population.
  - Describe the short-term impact: Detail the anticipated outcomes that will be directly attributed to the results of the proposed clinical trial. Outcomes should be specific, measurable, and should include a definition of the end user.
  - Describe the long-term impact: Explain the long-range vision for implementation of the intervention in the clinic or field, and describe the anticipated long-term benefits for the targeted population.
  - Compare the proposed intervention to pharmacologic agents, devices, and/or clinical guidance currently available (if applicable).
  - Summarize how the proposed project addresses one of the PCRP overarching challenges or another critical issue in prostate cancer research and/or patient care.

- **Attachment 12: Transition Plan (two-page limit).** Upload as “Transition.pdf.” Provide information on the methods and strategies proposed to move the product to the next level of clinical trials and ultimately delivery to the market after successful completion of the award. The transition plan should include the components listed below.
○ Details of the funding strategy that will be used to bring the outcomes to the next level of clinical trials and ultimately delivery to the market (e.g., specific potential industry partners, specific funding opportunities to be applied for, etc.).

○ A description of collaborations and other resources that will be used to provide continuity of development. For any industry partner(s), include a description of their product development and/or marketing experience.

○ A brief schedule and milestones for bringing the outcome(s) to the next level of clinical trials.

○ A risk analysis for cost, schedule, manufacturability, and sustainability.

• **Attachment 13: IND/IDE Documentation Form (if applicable):** Upload as “IND.IDE.pdf.”

  Complete the IND/IDE Documentation Form, which is available for download on the Full Announcement page for this Program Announcement/Funding Opportunity on Grants.gov.

3. **Research & Related Senior/Key Person Profile (Expanded) Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

   • PI Biographical Sketch (four-page limit): Upload as “Biosketch_LastName.pdf.”
   
   • PI Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”
   
   • Key Personnel Biographical Sketches (four-page limit each): Upload as “Biosketch_LastName.pdf.”
   
   • Key Personnel Current/Pending Support (no page limit): Upload as “Support_LastName.pdf.”

4. **Research & Related Budget:** Refer to the General Application Instructions, Section II.C., for detailed information.

   • Budget Justification (no page limit): Upload as “BudgetJustification.pdf.”

5. **Project/Performance Site Location(s) Form:** Refer to the General Application Instructions, Section II.C., for detailed information.

6. **R & R Subaward Budget Attachment(s) Form (if applicable):** Refer to the General Application Instructions, Section II.C., for detailed information.

**D. Submission Dates and Times**

All submission dates and times are indicated on the title page of this Program Announcement/Funding Opportunity. Pre-application and application submissions are required. Failure to meet any one of the deadlines shall result in application rejection.
E. Other Submission Requirements

Refer to the General Application Instructions, Appendix 2, for detailed formatting guidelines.

All applications must be submitted through Grants.gov. Organizations are required to provide a Data Universal Number System (DUNS) number and register with the Central Contractor Registry (CCR) to submit applications through the Grants.gov portal. Refer to the General Application Instructions, Appendix 3, for information on Grants.gov requirements.

III. APPLICATION REVIEW INFORMATION

A. Application Review and Selection Process

All applications are evaluated by scientists, clinicians, and consumer advocates using a two-tier review process. The first tier is a peer review of applications against established criteria for determining technical merit. The second tier is a programmatic review that compares applications to each other and makes recommendations for funding to the Commanding General, USAMRMC, based on technical merit, the relevance to the mission of the DOD and CDMRP, and the specific intent of the award mechanism. The highest scoring applications from the first tier of review are not automatically recommended for funding. Additional information about the two-tier review process used by the CDMRP can be found at http://cdmrp.army.mil/about/fundingprocess.

All CDMRP review processes are conducted confidentially to maintain the integrity of the merit-based selection process. Each level of review requires panelists to sign a non-disclosure statement attesting that application and evaluation information will not be disclosed outside the panel. Violations of the non-disclosure statement can result in the dissolving of a panel(s) and other corrective actions. Organizational personnel and PIs are prohibited from contacting persons involved in the review process to gain protected evaluation information or to influence the evaluation process. Violations of these prohibitions will result in the administrative withdrawal of the organization’s application. Violations by panelists or PIs that compromise the confidentiality of the review process may also result in suspension or debarment of their employing organizations from Federal awards. Furthermore, it is a crime for Federal officials to disclose confidential information of one party to another third party (Title 18 United States Code 1905).

B. Application Review Criteria

Peer Review: To determine technical merit, all applications will be evaluated according to the following scored criteria, which are of equal importance:

- Clinical Impact
  - To what degree the results of the proposed clinical trial will affect the magnitude and scope of potential clinical applications (e.g., detection, diagnosis, treatment, management, and/or quality of life).
  - To what degree the anticipated outcomes of the proposed clinical trial are relevant to individuals at various stages of prostate cancer.
○ How well the sample population represents the targeted patient population that might benefit from the proposed intervention.

○ To what degree the potential outcomes of the proposed clinical trial will provide/improve the short- and long-term benefits for individuals.

○ To what degree the intervention advances patient care beyond the currently available interventions.

○ How well the proposed research addresses one of the PCRP overarching challenges or is otherwise justified as significantly addressing another critical issue in prostate cancer research and/or patient care.

• Intervention

○ To what degree the intervention addresses the clinical need(s) described.

○ To what degree the plans for application of the intervention (e.g., dosing, schedule) are appropriate.

○ Whether there is evidence to support availability of and access to, if applicable, the intervention for the proposed clinical trial.

○ Whether there is sufficient evidence to support that an IND/IDE is in place, if applicable.

○ Whether measures are described to ensure the consistency of dosing of active ingredients for nutritional supplements, if applicable.

• Research Strategy

○ How well the scientific rationale for testing the intervention is supported by the preliminary data, critical review and analysis of the literature, and/or laboratory and/or preclinical evidence.

○ To what extent the study aims, hypotheses or objectives, experimental design, methods, data collection procedures, and analyses are designed to clearly answer the clinical objective.

○ To what degree the data collection instruments (e.g., surveys, questionnaires, etc.), if applicable, are appropriate to the proposed study.

○ How well the inclusion and randomization criteria meet the needs of the proposed clinical trial.

○ How well the exclusion criteria are justified.

• Recruitment, Accrual, and Feasibility

○ How well the PI addresses the availability of human subjects for the clinical trial and the prospect of their participation.

○ Whether the PI has demonstrated sufficient degree of access to the proposed human subjects population.

○ How well the recruitment, informed consent, screening, and retention processes for human subjects are designed to meet the needs of the proposed clinical trial.
○ Whether there is evidence of an adequate contingency plan to resolve potential delays (e.g., slow accrual, attrition).

○ To what extent the PI has adequately considered and develop mitigation plans for any effects of the proposed clinical trial on the daily lives of the individual human subjects participating in the study (e.g., Will human subjects still be able to take their regular medications while participating in the clinical trial? Are human subjects required to stay overnight in a hospital?).

• **Statistical Plan**
  ○ To what degree the statistical plan, including sample size projections and power analysis, is appropriate and adequate for the study and all proposed correlative studies.

• **Ethical Considerations**
  ○ How well the level of risk to human subjects is minimized.
  ○ How well the evidence shows that the procedures are consistent with sound research design and, when appropriate, that these procedures are already in use for diagnostic or treatment purposes.
  ○ To what degree privacy issues are appropriately considered.
  ○ To what degree the process for seeking informed consent is appropriate, and whether safeguards are in place for vulnerable populations.

• **Transition Plan**
  ○ Whether the funding strategy described to bring the outcome(s) to the next level of clinical trials and/or delivery to the military or civilian market is appropriate.
  ○ Whether appropriate collaborations and other resources for providing continuity of development are established and/or well described.
  ○ To what degree the schedule and milestones for bringing the outcome(s) to clinical trial and/or delivery to the military or civilian market are appropriate.
  ○ How well the potential risk analysis for cost, schedule, manufacturability, and sustainability is developed.

In addition, the following unscored criteria will also contribute to the overall evaluation of the application:

• **Personnel and Communication**
  ○ Whether the composition of the study team (e.g., study coordinator, statistician) is appropriate.
  ○ To what degree the PI’s and study team’s backgrounds and expertise are appropriate to accomplish the proposed work (e.g., statistical expertise, expertise in the disease, and clinical trial experience).
○ How the levels of effort of the study team members are appropriate for successful conduct of the proposed trial.

○ To what degree the logistical aspects of the proposed clinical trial (e.g., communication plan, data transfer, standardization of procedures) are adequate.

• **Environment**
  ○ To what degree the scientific environment, clinical setting, and the accessibility of institutional resources support the clinical trial at each participating center or institution (including collaborative arrangements).
  ○ Whether there is evidence for appropriate institutional commitment from each participating institution.
  ○ If applicable, to what degree the intellectual and material property plan that is agreed upon by each participating institution is appropriate for the proposed clinical trial.

• **Budget**
  ○ Whether the budget is appropriate for the proposed research and within the limitations of this Program Announcement/Funding Opportunity.
  ○ If the study requires funds beyond those provided by this award to be fully supported to its planned completion, whether the additional sources of funding are sufficiently described.

• **Application Presentation**
  ○ To what extent the writing, clarity, and presentation of the application components influenced the review.

**Programmatic Review:** To determine the application’s relevance to the mission of the DOD and CDMRP, as well as to make funding recommendations, the following equally considered criteria are used by programmatic reviewers:

- Adherence to the intent of the award mechanism
- Programmatic relevance
- Ratings and evaluations of the peer reviewers
- Relative impact
- Program portfolio composition

C. **Recipient Qualification**

Refer to the General Application Instructions, Appendix 1, for additional information on organization and Government agency requirements.
D. Application Review Dates

All application review dates and times are indicated on the title page of this Program Announcement/Funding Opportunity.

E. Notification of Application Review Results

Each PI and organization will receive notification of the funding recommendation. PIs will receive a scientific peer review summary statement on the strengths and weaknesses of the application.

IV. ADMINISTRATIVE ACTIONS

After receipt of pre-applications from CDMRP eReceipt or applications from Grants.gov, the following administrative actions may occur:

A. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative exceeds page limit.
- Preproposal Narrative is missing.

The following will result in administrative rejection of the application:

- Project Narrative exceeds page limit.
- Project Narrative is missing.
- Budget is missing.
- Human Subject Recruitment and Safety Procedures attachment (Attachment 6) is missing.
- Intervention attachment (Attachment 7) is missing.
- Data Management attachment (Attachment 8) is missing.
- Submission of an application for which a letter of invitation was not received.

B. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents other than the Project Narrative and Preproposal Narrative.
- Documents not requested will be removed.
- Following the application deadline, you may be contacted by CDMRP via email with a request to provide certain missing supporting documents (excluding those listed in Section IV.A., Rejection). The missing documents must be provided by 5:00 p.m. ET on the second full business day following the date the email was sent. Otherwise, the application will be reviewed as submitted.
C. Withdrawal

The following may result in administrative withdrawal of the pre-application or application:

- FY11 PCRP IP member is found to be involved in the pre-application or application processes including, but not limited to, concept design, application development, budget preparation, and the development of any supporting document. A list of the FY11 PCRP IP members may be found at http://cdmrp.army.mil/pcrp/panels/panel11.
- Submission of the same research project to different funding opportunities within the same program and fiscal year.
- The application does not conform to this Program Announcement/Funding Opportunity description to an extent that precludes appropriate review.
- Direct costs as shown on the Research and Related Budget form exceed the maximum allowed by this Program Announcement/Funding Opportunity.
- Inclusion of URLs with the exception of links to published references.
- Page size is larger than 8.5 inches x 11.0 inches (approximately 21.59 cm x 27.94 cm).
- The proposed research project is not a clinical trial.
- The PI does not meet the eligibility criteria.
- The PI of the application is not the same PI as proposed in the pre-application.
- An existing IND/IDE for the intervention, if applicable, is not demonstrated.

D. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending institutional investigation. The institution will be required to provide the findings of the investigation to the US Army Medical Research Acquisition Activity (USAMRAA) Contracting/Grants Officer for a determination of the final disposition of the application.

V. AWARD ADMINISTRATION INFORMATION

A. Award Notice

Awards will be made no later than September 30, 2012. Refer to the General Application Instructions, Appendix 4, for additional award administration information.

B. Administrative and National Policy Requirements

Refer to the General Application Instructions, Appendix 4, Section C, for general information regarding administrative and national policy requirements.
C. Reporting

Refer to the General Application Instructions, Appendix 4, Section D, for general information on reporting requirements.

Quarterly technical progress reports will be required.

D. Award Transfers

Refer to the General Application Instructions, Appendix 4, Section E, for general information on organization or PI changes.

The transfer of an award to another institution is strongly discouraged. A transfer will not be allowed for any institution that includes a study site/clinical trial at its location. Approval of a transfer request from an institution that does not include a study site at its location will be at the discretion of the Grants Officer.

E. Pre-Award Meeting

At the Government’s discretion, the PI and Clinical Study Coordinator may be requested to participate in a pre-award meeting.

VI. AGENCY CONTACTS

A. CDMRP Help Desk

Questions related to Program Announcement/Funding Opportunity content or submission requirements and questions related to the submission of the pre-application through the CDMRP eReceipt System should be directed to the CDMRP Help Desk, which is available Monday through Friday from 8:00 a.m. to 5:00 p.m. ET. Response times may vary depending upon the volume of inquiries.

Phone: 1-301-682-5507
Email: help@cdmrp.org

B. Grants.gov Contact Center

Questions related to application submission through the Grants.gov portal should be directed to the Grants.gov Contact Center, which is available 24 hours a day, 7 days a week (closed on U.S. Federal holidays). Note that the CDMRP Help Desk is unable to provide technical assistance with Grants.gov submission.

Phone: 1-800-518-4726
Email: support@grants.gov

Sign up on Grants.gov for “send me change notification emails” by following the link on the Synopsis page for the Program Announcement/Funding Opportunity. If the application package is updated or changed, the original version of the application package may not be accepted by Grants.gov.
## VII. APPLICATION SUBMISSION CHECKLIST

<table>
<thead>
<tr>
<th>Grants.gov Application Components</th>
<th>Action</th>
<th>Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-424 (R&amp;R) Application for Federal Assistance Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>Attachments Form</td>
<td>Upload Project Narrative (ProjectNarrative.pdf) as Attachment 1.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Supporting Documentation (Support.pdf) as Attachment 2.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Technical Abstract (TechAbs.pdf) as Attachment 3.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Public Abstract (PublicAbs.pdf) as Attachment 4.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Statement of Work (SOW.pdf) as Attachment 5.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Human Subject Recruitment and Safety Procedures (HumSubProc.pdf) as Attachment 6.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Intervention (Intervention.pdf) as Attachment 7.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Data Management (Data_Manage.pdf) as Attachment 8.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Study Personnel and Organization (Personnel.pdf) as Attachment 9.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Surveys, Questionnaires, and Other Data Collection Instruments (Surveys.pdf), if applicable, as Attachment 10.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Impact Statement (Impact.pdf) as Attachment 11.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload Transition Plan (Transition.pdf) as Attachment 12.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upload IND/IDE Documentation Form (IND.IDE.pdf), if applicable, as Attachment 13.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Senior/Key Person Profile (Expanded)</td>
<td>Attach PI Biographical Sketch (Biosketch_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach PI Current &amp; Pending Support (Support_LastName.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Biographical Sketch (Biosketch_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Attach Current &amp; Pending Support (Support_LastName.pdf) for each senior/key person to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Research &amp; Related Budget</td>
<td>Complete form as instructed. Attach Budget Justification (BudgetJustification.pdf) to the appropriate field.</td>
<td></td>
</tr>
<tr>
<td>Project/Performance Site Location(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
<tr>
<td>R &amp; R Subaward Budget Attachment(s) Form</td>
<td>Complete form as instructed.</td>
<td></td>
</tr>
</tbody>
</table>